CSL Ltd Offers to Acquire 100% of Vifor Pharma Ltd Transcript
Thank you for standing by, and welcome to the CSL Investor Briefing.
(Operator Instructions)
I would now like to hand the conference over to Mark Dehring, Head of Investor Relations. Please go ahead.
Good. Thanks, operator, and good evening, ladies and gentlemen. Welcome to CSL's briefing on today's announcement about the tender offer to acquire 100% of Vifor Pharma Ltd. As just mentioned, it's Mark Dehring speaking, and joining me online is Paul Perreault CSL's Chief Executive Officer; Joy Linton, CSL's Chief Financial Officer; and Bill Mezzanotte, CSL's Executive VP, Head of Research and Development and Chief Medical Officer. And Paul will be providing an overview of the transaction highlights. Then Joy will provide some additional detail on the financials. And then, of course, we do have an opportunity for Q&A.
(Operator Instructions) Please note, this briefing is being recorded. And lastly, before we start, I draw your attention to the core statement disclaimer contained in the slide
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |